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(95%). From their past experience, 21% of them mentioned that they seldom get their 
drugs labeled whereas 14% of the total respondents were not sure whether they get 
their drugs labeled or not. In this study, gender, age, and level of education showed 
signiﬁ cant associations with most responses (P < 0.05). CONCLUSIONS: General 
public in Malaysia are aware about the importance of drug labeling and about one 
ﬁ fth of the population surveyed rarely receive their medicines labeled appropriately. 
Therefore, decision makers have to strictly enforce the existing drug labeling require-
ments for dispensed medications.
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OBJECTIVES: Patient satisfaction, in response to a treatment, is an element of the 
medical service rendered. We quantiﬁ ed the satisfaction of patients treated medically 
for urinary disorders. METHODS: A pragmatic cohort (France, Italy, and Portugal) 
of 420 patients treated with Serenoa Repens, α-blocker or 5 α-reductase inhibitor, 
was followed-up for 6 months. RESULTS: A total of 175 patients were evaluated. 
Satisfaction was expressed as the differential between the expectation of the patients 
recorded before the start of treatment and the status declared at 6 months. In addition 
a binary (yes/no) question regarding general satisfaction was used as the primary 
evaluation criterion. We observed positive satisfaction in 61.7% of subjects in terms 
of the “effort or force needed to start urinating”, 51.1% for the “size and force of 
the stream of urine”, 54.35% for “sensation of not emptying the bladder after urinat-
ing”, 52.38% for “interrupting the ﬂ ow”, and 50% for the “need to urinate”. We 
observed negative satisfaction in 68.18% of subjects with respect to the progression 
of “getting up in the night to urinate”. At 6 months, the response to the general 
satisfaction question conﬁ rms these initial results—indeed, nearly 98% of subjects 
were satisﬁ ed with the treatment of their BPH. We did not see any signiﬁ cant difference 
between the 3 treatment groups. CONCLUSIONS: The individualised expectation of 
the patient will undoubtedly be one of the major preoccupations of the next few 
decades. Medical treatment for BPH is accompanied by a satisfaction that is compat-
ible with long term compliance with the treatment by the patient.
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OBJECTIVES: The individualised expectations of the patient will undoubtedly be one 
of the major preoccupations in the next few decades to guarantee optimal treatment 
through compliance. METHODS: A pragmatic, European cohort (France, Italy, and 
Portugal) of 420 patients presenting with urinary disorders, evocative of BPH, was 
followed-up over 6 months. a questionnaire regarding expectations was handed out 
at the ﬁ rst consultation. RESULTS: A total of 317 patients were evaluated. The 
symptoms that 30.7% of patients wished to see improved with the highest priority 
were “getting up in the night to urinate”, then for slightly less than 20%, “sensation 
of not emptying the bladder after urinating”. Amongst the symptoms that patients 
were the least concerned about were “the effort or force needed to start urinating” 
for 23% of responders, then “the interruption of the ﬂ ow of urine” for 16% and the 
“size and force of the stream of urine”. “Getting up in the night” was the principal 
complaint in all 3 countries (39% in France, 26 and 25% in Italy and Portugal), simi-
larly “the effort or force needed to start urinating” is the symptom that preoccupies 
the patients the least in France and Italy, the “size and force of the stream of urine” 
preoccupies the Portuguese the least. Nearly 90% of the Italians claimed that they 
would only be satisﬁ ed if they never had to get up in the night again, (35% for the 
French, 50% for the Portuguese). Overall, 60% of the subjects questioned said that 
they would be satisﬁ ed if they were “markedly” improved. CONCLUSIONS: The 
expectation of patients in the treatment of BPH is very important, and undoubtedly 
difﬁ cult to satisfy entirely. These results are probably due to the fact that our popula-
tion was composed of patients that had been diagnosed recently.
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OBJECTIVES: To evaluate the effect of E2V/DNG, an oral contraceptive, on WP 
(presenteeism) and ADL outcomes in HPMB sufferers using an appropriate analytical 
strategy. METHODS: This was a post-hoc analysis of patient-reported outcomes from 
two multicenter, randomized, placebo-controlled trials in North America and Europe/
Australia that evaluated the efﬁ cacy of E2V/DNG in women with HPMB. Data were 
collected using a modiﬁ ed Work Productivity and Activities Impairment questionnaire. 
WP and ADL outcomes were measured on a 10-point Likert scale. The analytical 
strategy was developed to determine and apply the most appropriate statistical method-
ology given the data and methodological challenges, including highly-skewed, incom-
plete, multi-country data, unbalanced enrolment across countries, and the auto-regressive 
nature of the outcomes. The analyses progressed from descriptive statistics to Bayesian 
regression in several sequential steps. The underlying model chosen for Bayesian analyses 
was simultaneous equation modeling to incorporate temporal aspects and potential 
cross-country heterogeneity. RESULTS: The data set included 416 patients (E2V/DNG, 
n = 265; placebo, n = 151) across 12 countries. In all analytical approaches, E2V/DNG 
vs. placebo treatment showed signiﬁ cantly positive effects on WP and ADL at a magni-
tude of a one-point change on the Likert scale (based on linear regression analysis). In 
Bayesian analyses, Gamma distribution yielded a better model ﬁ t (DIC = 2129.01 vs. 
2460.12 for normal distribution [presenteeism] and DIC = 2313.33 vs. 2640.36 [ADL]). 
The average treatment effect on presenteeism for Gamma distributed models was −0.82 
(95%CI: −1.37, −0.34) at treatment day 84 and −1.06 (95%CI: −1.67, −0.56) at treat-
ment end (EOT; day 196). The average treatment effect on ADL was −1.07 (95%CI: 
−1.70, −0.52) at day 84 and −1.09 (95%CI: −1.63, −0.62) at EOT. CONCLUSIONS: 
E2V/DNG has a statistically signiﬁ cant and positive impact on presenteeism and ADL 
impairment. The robustness of these ﬁ ndings was conﬁ rmed by the application of several 
methodological approaches, with Bayesian analyses appropriately dealing with identiﬁ ed 
methodological challenges.
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OBJECTIVES: A large proportion of patients are non-adherent to anti-osteoporotic 
treatments within 12 months of initiation. In the health psychology literature, several 
behavioural models have been developed to explain non-adherence, most notably the 
Health Belief Model (HBM). Based on these, our study aimed to explore determinants 
of persistence (i.e., continuation) with anti-osteoporotic treatments. METHODS: A 
psychologist carried out face-to-face interviews with patients who had taken anti-
osteoporotic treatment for 2 years. Interviews were based on a guide including ques-
tions on beliefs and experiences with osteoporosis and its treatment. Saturation was 
reached with 16 patients providing over 95% of information. Content analysis of 
interview transcripts was performed to highlight criteria that determine intentions 
regarding treatment continuation. RESULTS: Through patient interview analysis, 
determinants with an effect on persistence were categorized either as barriers or facili-
tators. While general health behaviour was identiﬁ ed in both type of determinants, 
barriers to persistence included: Disease perceived as non-severe (“osteoporosis is not 
a severe disease, perhaps not a disease at all”); Treatment side-effects (“there are 
side-effects, I suffer from allergies, I am hesitant to take treatment”) and Constraints 
(“you have to take treatment every day”; “you have to wait 2 hours after dinner before 
taking treatment”). Facilitators included: Perceived beneﬁ ts (“my treatment works, 
bone mineral density results are good”); Habit/maintenance (“I take my treatment 
because I am used to it, I do not question it”) and Relationship with doctor (“I have 
conﬁ dence in my doctor”). CONCLUSIONS: Results are consistent with the health 
psychology models, in particular the HBM. They add new concepts to HBM. Results 
suggest that areas for improvement in persistence in osteoporosis lay in beliefs about 
disease and treatment efﬁ cacy, rather than treatment convenience.
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OBJECTIVES: Patient-Reported Outcomes(PRO) is the information on treatment 
evaluations that comes directly from a patient. PRO is derived from every endpoint 
from patient reports. These reports have been recorded in a patient diary or other 
reporting systems. PRO is an important tool for measuring the impact of diseases, 
treatments, health and social polices like pharmacoeconomic polices. The objective of 
this study is to determine the level and nature of the use of PRO compared to other 
endpoints for Korea’s approved new drugs. METHODS: A survey has been conducted 
for 121 newly approved products in Korea during the period of 2005 to 2009. Dif-
ferent survey forms were prepared for each product. Each survey form provided 
information on products and clinical trials: title, objectives, types of endpoints, types 
of PRO and the information on PRO sent by e-mail to the manager of each pharma-
ceutical company. RESULTS: Primary endpoints were measured in 200 clinical trials 
whereas secondary endpoints were measured in 183 clinical trials. The two both 
studied 111 products. For PRO, a primary endpoint was reported in 33(14.6%) trials 
and a secondary has been reported in 66(25.1%) trials. For Clinician-reported out-
comes, the ﬁ gures were 104(46.0%) and 108(41.1%), respectively. For Laboratory/
device endpoints, the ﬁ gures were 89(39%) and 89(33.7%), respectively. For 11 
products, PROs have been used as the only type of endpoint. About 40 percent of 
PROs have been used as primary and secondary endpoints in clinical trials for drug 
approval during the last ﬁ ve years(2005~2009). However, the results of the PRO 
secondary endpoints have not been reﬂ ected in product labeling. CONCLUSIONS: 
PRO has been used as a useful endpoint that can be employed in clinical trials for the 
development and evaluation of new drugs. Therefore, it is necessary to develop PRO 
instruments and guidelines to evaluate Korean patients’ PRO for Koreans and clinical 
trials at home.
